SOLACE2
24 Nov 2020
SOLACE2
ACTRN12618000686202
A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects.
ANZGOG
Cancer Type | Gynaecological |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | Female |
Tumour Stream | ovarian, fallopian tube or primary peritoneal cancers |
Cancer Stage | All stages |
Anticipated Start Date | 2018-07-15 |
Anticipated End Date | 2024-08-31 |
Hospital | Flinders Medical Centre |
---|---|
Clinical Trial Coordinator | Hannah Adelson |
Hannah.adelson@sa.gov.au | |
Phone | 08 8206 4835 |
Principal Investigator | Dr Shawgi Sukumaran |
Recruitment Status | Recruiting |
Hospital | Royal Adelaide Hospital |
---|---|
Clinical Trial Coordinator | Anne Milton |
anne.milton@sa.gov.au | |
Phone | 08 7074 2342 |
Principal Investigator | Dr Sid Selva |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs